Memorializing Governor Kathy Hochul to proclaim May 2025, as Neurofibromatosis Month in the State of New York
Summary
This resolution memorializes Governor Kathy Hochul to proclaim May 2025 as Neurofibromatosis Month in New York State. It is a commemorative measure intended to raise public awareness of neurofibromatosis (NF), a serious tumor disorder that affects an estimated 130,000 Americans, and to recognize the work of advocacy and research organizations such as Neurofibromatosis Northeast.
The resolution highlights the importance of education, research, early diagnosis, and access to knowledgeable clinicians for people living with NF and their families. It references recent medical progress, including FDA approval of Koselugo (selumetinib) for NF1 and ongoing clinical trials involving combination, gene, and bacterial therapies, as reasons to continue building awareness and support for treatment and cure efforts.
Impact
As a resolution, this measure does not amend the New York Consolidated Laws or create enforceable rights or duties. Its legal effect is limited to formally requesting that the Governor issue a proclamation designating May 2025 as Neurofibromatosis Month and to transmitting that message to the Governor. Its practical impact is symbolic and promotional: it may help elevate public awareness, encourage research and advocacy, and draw attention to affected patients, families, clinicians, and nonprofit organizations.
Sentiment
The overall sentiment is strongly supportive and noncontroversial. The text frames the resolution as a customary legislative recognition of an important health awareness month and emphasizes compassion for affected individuals, support for research, and appreciation for advocacy groups and medical professionals. No votes, committee transcripts, or recorded opposition are provided, and nothing in the available record suggests substantive disagreement.
Contention
There is little to no apparent contention in the available materials because the measure is a ceremonial resolution rather than a policy bill. The only implicit point of emphasis is the call for greater awareness and more activity at the local, state, and national levels to support NF research and treatment. Any differences of view would likely be about the value of proclamations and awareness campaigns generally, but no specific objections are documented here.